Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Carbenoxolone disrupts cell migration by inhibiting the SERCA pump

Created on 18 Aug 2026

Authors

Sanchez, C., Calvo, B., Palii, S., Adler, M. R., Cortes, J. L., Conze, C., Jimenez, A., Gallegos, M. L., Uhrig, U., Schimmang, T., Rojo, J., Saez, P. J., Alonso, M. T.

Abstract

Collective cell migration is a fundamental process driving tissue repair, angiogenesis, and vascular homeostasis. This coordinated movement requires both intercellular communication via gap junctions and precise intracellular Ca2+ signaling, largely regulated by the sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA) pump within the endoplasmic reticulum (ER). Historically, carbenoxolone (CBX), a synthetic derivative of glycyrrhetinic acid, has been widely utilized as a pharmacological tool to inhibit gap junctions and dissect their role in collective cell motility. However, its molecular specificity remains highly controversial. In the present study, using different cellular models, we found that CBX drastically reduces collective cell migration by a previously undescribed function for CBX: a fast, potent, and reversible inhibition of the SERCA pump, which provokes a passive leak of the luminal ER Ca2+ store. Our findings suggest that the effect of CBX over many cellular responses including cell migration and communication, previously only attributed to gap junction blockade, are indeed the consequence of the disruption of intracellular Ca2+ homeostasis.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 18 Aug 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 27
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement